Audiocure is a dedicated brand that aims to turn incurable hearing loss into a treatable event. They are focused on the development of drug treatments for hearing disorders that have a high unmet medical need. Unlike traditional approaches that only treat symptoms, Audiocure's therapeutic approach targets the root cause of the disorders by protecting and restoring critical cellular players involved in the hearing process.

Currently, there are no approved drugs for the treatment of sensorineural hearing loss disorder or tinnitus. However, Audiocure Pharma is determined to change this. Their lead candidate, AC102, is a novel molecule that has shown promise in preclinical models by protecting and restoring cells and their connections in the inner ear.

AC102 has the potential to be the first breakthrough causative therapy for acute hearing loss and acute tinnitus. With over 360 million people worldwide suffering from some form of hearing loss, Audiocure recognizes the significant unmet medical need for effective treatments. Their team of specialists is focused on taking a comprehensive approach to develop novel pharmacotherapies for inner ear disorders.

By addressing this treatment gap, Audiocure is working towards changing the landscape for individuals affected by hearing disorders